Search Within

Aseem Anand

Formats
  1. Meeting Abstract (42)
  2. Journal Article (19)
Groups
  1. Department of Medicine (52)
  2. Genitourinary Oncology Service (52)
  3. Solid Tumor Oncology Division (52)
  4. Epidemiology and Biostatistics (21)
  5. GSK Faculty (21)
  6. Biostatistics Service (20)

More Groups

People
  1. Howard Scher (46)
  2. Martin Fleisher (34)
  3. Daniel Danila (33)
  4. Glenn Heller (19)
  5. Michael Morris (15)
  6. Hans Lilja (10)

More People

Years
  1. 2025 (1)
  2. 2022 (3)
  3. 2020 (1)
  4. 2019 (2)
  5. 2018 (2)
  6. 2017 (2)

More Years

Publications
  1. Journal of Clinical Oncology (35)
  2. Clinical Cancer Research (3)
  3. Journal of Nuclear Medicine (3)
  4. Clinical Chemistry (2)
  5. European Urology (2)
  6. Journal of Molecular Diagnostics (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (35)
  2. Elsevier Science, Inc. (6)
  3. American Association for Cancer Research (5)
  4. Society of Nuclear Medicine (3)
  5. Springer (3)
  6. American Association for Clinical Chemistry (2)

More Publishers

Results (61)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A validated whole-blood RNA transcript-based prognostic model that predicts survival in men with castration-resistant prostate cancer
    Meeting Abstract

    Oh, W. K.; Kantoff, P.; Scher, H. I.; Magidson, J.; Wassmann, K.; Lee, G. S. M.; Katz, L. M.; Subudhi, S. K.; Anand, A.; Fleisher, M.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Predictive biomarkers in circulating tumor cells (CTC) from patients with castration-resistant prostate cancer (CRPC) through genomic analysis
    Meeting Abstract

    Danila, D. C.; Anand, A.; Yao, J.; Gierszewska, M.; Kramer, M.; Muller, S.; Fleisher, M.; McCombie, W. R.; Scher, H. I.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Predictive biomarkers in circulating tumor cells (CTC) from patients with castration-resistant prostate cancer (CRPC) through genomic analysis
    Meeting Abstract

    Danila, D. C.; Anand, A.; Yao, J.; Gierszewska, M.; Kramer, M.; Muller, S.; Fleisher, M.; McCombie, W. R.; Scher, H. I.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A pilot study comparing the sensitivity of detecting prostate associated transcripts by adna test prostate assay to cell search in whole blood from patients with castration resistant prostate cancer
    Meeting Abstract

    Samoila, A.; Wan, M.; Anand, A.; Chuang, T.; Scher, H. I.; Fleisher, M.; Danila, D. C.
    Journal of Molecular Diagnostics (2012)

    Fulltext@MSK | Save
  • The analytical validation of prostate specific mRNA detection in whole blood by reverse transcription-polymerase chain reaction (RT-PCR) as a prognostic biomarker for patients with castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Danila, D.; Anand, A.; Heller, G.; Wan, M.; Zehnder, M.; Khanin, R.; Schultz, N.; Fleisher, M.; Lilja, H.; Scher, H. I.
    Annals of Oncology (2012)

    Fulltext@MSK | Save
  • A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: A prospective study
    Journal Article

    Ross, R. W.; Galsky, M. D.; Scher, H. I.; Magidson, J.; Magidson, K.; Lee, G. S. M.; Katz, L.; Subudhi, S. K.; Anand, A.; Fleisher, M.; more...
    Lancet Oncology (2012)

    Fulltext@MSK | Save
  • Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel
    Meeting Abstract

    Scher, H. I.; Heller, G.; Molina, A.; Kheoh, T. S.; Attard, G.; Moreira, J.; Sandhu, S. K.; Parker, C.; Logothetis, C.; McCormack, R. T.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • A six-gene panel that predicts survival in men with castration-resistant prostate cancer
    Meeting Abstract

    Subudhi, S. K.; Heller, G.; Anand, A.; Danila, D. C.; Fleisher, M.; Scher, H. I.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Genomic analysis of circulating tumor cells (CTC) from patients with castration-resistant prostate cancer (CRPC) as predictive biomarkers
    Meeting Abstract

    Danila, D. C.; Anand, A.; Yao, J.; Gierszewska, M.; Kramer, M.; Muller, S.; Fleisher, M.; McCombie, W. R.; Scher, H. I.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Antitumor activity of MDV3100 in pre- and post-docetaxel advanced prostate cancer: Long-term follow-up of a phase I/II study
    Meeting Abstract

    Higano, C. S.; Beer, T. M.; Taplin, M.; Efstathiou, E.; Anand, A.; Hirmand, M.; Fleisher, M.; Scher, H. I.; for the Prostate Cancer Clinical Trials Consortium
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save